Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Moderate to Severe Alopecia Areata
NCT01950780Phase 2Completed
- Sponsor
- Columbia University
- Start
- Aug 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in alopecia areata, sponsored by Columbia University. Primary endpoint: Change in Severity of Alopecia Tool Score at 6 months. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT01950780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01950780.